88 related articles for article (PubMed ID: 27262540)
1. Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Collins JB; Muluneh B; Profitt S
J Oncol Pharm Pract; 2024 Mar; 30(2):385-396. PubMed ID: 38105466
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions.
Rea D; Fodil S; Lengline E; Raffoux E; Cayuela JM
Curr Hematol Malig Rep; 2024 Jun; 19(3):104-110. PubMed ID: 38393431
[TBL] [Abstract][Full Text] [Related]
3. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.
Cross NCP; Ernst T; Branford S; Cayuela JM; Deininger M; Fabarius A; Kim DDH; Machova Polakova K; Radich JP; Hehlmann R; Hochhaus A; Apperley JF; Soverini S
Leukemia; 2023 Nov; 37(11):2150-2167. PubMed ID: 37794101
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.
Dahlén T; Edgren G; Lambe M; Höglund M; Björkholm M; Sandin F; Själander A; Richter J; Olsson-Strömberg U; Ohm L; Bäck M; Stenke L;
Ann Intern Med; 2016 Aug; 165(3):161-6. PubMed ID: 27295519
[TBL] [Abstract][Full Text] [Related]
5. 'Real-life' study of imatinib therapy in chronic phase-chronic myeloid leukemia: A novel retrospective observational longitudinal analysis.
Merante S; Ferretti V; Elena C; Calvello C; Rocca B; Zappatore R; Cavigliano P; Orlandi E
Hematology; 2017 Jan; 22(1):1-8. PubMed ID: 27320082
[TBL] [Abstract][Full Text] [Related]
6. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the Use of TKIs in the Management of Chronic Myelogenous Leukemia.
Ruiz-Cordell K; Haimowitz S; Gracie-King L; Middleton D
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):442-6. PubMed ID: 27289562
[TBL] [Abstract][Full Text] [Related]
8. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre PD; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Lustgarten S; Rivera VM; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes TP; Shah NP; Kantarjian HM
Blood; 2018 Jul; 132(4):393-404. PubMed ID: 29567798
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Rosti G; Castagnetti F; Gugliotta G; Baccarani M
Nat Rev Clin Oncol; 2017 Mar; 14(3):141-154. PubMed ID: 27752053
[TBL] [Abstract][Full Text] [Related]
10. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A; Baccarani M; Silver RT; Schiffer C; Apperley JF; Cervantes F; Clark RE; Cortes JE; Deininger MW; Guilhot F; Hjorth-Hansen H; Hughes TP; Janssen JJWM; Kantarjian HM; Kim DW; Larson RA; Lipton JH; Mahon FX; Mayer J; Nicolini F; Niederwieser D; Pane F; Radich JP; Rea D; Richter J; Rosti G; Rousselot P; Saglio G; Saußele S; Soverini S; Steegmann JL; Turkina A; Zaritskey A; Hehlmann R
Leukemia; 2020 Apr; 34(4):966-984. PubMed ID: 32127639
[TBL] [Abstract][Full Text] [Related]
11. Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review.
Desai A; Lovly CM
Transl Lung Cancer Res; 2023 Mar; 12(3):615-628. PubMed ID: 37057106
[TBL] [Abstract][Full Text] [Related]
12. Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model.
Pinto CA; DE Sousa Portilho AJ; Barbosa MC; DE Moraes MEA; DE Lemos JAR; Burbano RMR; Moreira-Nunes CA
In Vivo; 2021; 35(5):2661-2667. PubMed ID: 34410954
[TBL] [Abstract][Full Text] [Related]
13. The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice.
Galimberti S; Genuardi E; Mazziotta F; Iovino L; Morabito F; Grassi S; Ciabatti E; Guerrini F; Petrini M
Front Oncol; 2019; 9():528. PubMed ID: 31293969
[TBL] [Abstract][Full Text] [Related]
14. Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question.
Sweet K; Pinilla-Ibarz J
Crit Rev Oncol Hematol; 2016 Jul; 103():99-108. PubMed ID: 27262540
[TBL] [Abstract][Full Text] [Related]
15. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
Caldemeyer L; Akard LP
Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
[TBL] [Abstract][Full Text] [Related]
16. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S
Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681
[TBL] [Abstract][Full Text] [Related]
17. NCCN and ELN: What do the guidelines tell us?
Sweet K; Pinilla-Ibarz J
Best Pract Res Clin Haematol; 2016 Sep; 29(3):264-270. PubMed ID: 27839567
[TBL] [Abstract][Full Text] [Related]
18. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
19. Molecular monitoring of chronic myeloid leukemia: present and future.
Yeung CC; Egan D; Radich JP
Expert Rev Mol Diagn; 2016 Oct; 16(10):1083-1091. PubMed ID: 27552202
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
